Atypical Hemolytic Uremic Syndrome (aHUS)
Hematology·MeSH: Atypical Hemolytic Uremic Syndrome
Prevalence
0.1 / 100K
2 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| Ultomiris | Xencor Inc (XNCR) |
Phase 2(1)
| Drug | Company |
|---|---|
| ra101495 sc | RA PHARMACEUTICALS, INC. (RARX) |
Compare drugs
Frequently asked questions
How many drugs are in development for Atypical Hemolytic Uremic Syndrome (aHUS)?
BioSniper tracks 2 drugs in development for Atypical Hemolytic Uremic Syndrome (aHUS) across 2 companies.
How many clinical trials target Atypical Hemolytic Uremic Syndrome (aHUS)?
There are 1 clinical trial targeting Atypical Hemolytic Uremic Syndrome (aHUS) tracked by BioSniper.
What is the prevalence of Atypical Hemolytic Uremic Syndrome (aHUS)?
The estimated prevalence of Atypical Hemolytic Uremic Syndrome (aHUS) is approximately 0.1 per 100,000 population.
Deep-dive into Atypical Hemolytic Uremic Syndrome (aHUS)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis